Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology Drug Updates: Opioid CR845 for OA Pain; RA Treatments in Development

Michele B. Kaufman, PharmD, BCGP  |  March 15, 2016

CR845—an oral, peripherally selective kappa opioid agonist—is currently in Phase 2 trials for the treatment of pruritus, and acute and chronic pain.1 Eighty patients with hip osteoarthritis (OA) or knee OA were randomized to receive treatment with 0.25 mg, 0.5 mg, 1.0 mg or 5.0 mg CR845 twice daily for two weeks. Safety assessment, pharmacokinetics…

What Rheumatologists Need to Know about Payer Audits

Steven M. Harris, Esq.  |  March 15, 2016

Both government and private payers continue to aggressively monitor providers to prevent and recover overpayments. This is evidenced by the fact that the number of audits conducted in recent years has increased dramatically. A negative audit finding can result in the need to repay five- or seven-figure amounts. Types of Audits Private Payer Audits Private…

Ballroom Dancing Helps Improve Pharmacist’s Teaching Skills

Carol Patton  |  March 15, 2016

Slow, slow, quick, quick. Don Miller, PharmD, has repeated that phrase to himself countless times over the past 40 years. Since the 1980s, Dr. Miller, a professor of pharmacy practice in the College of Health Professions at North Dakota State University (NDSU), has been a competitive ballroom dancer. Repeating that phrase is common to all…

Opinion: Paris Terrorist Attacks Shouldn’t Keep Rheumatologists from Attending Next ACR/ARHP Annual Meeting

Katarzyna Gilek-Seibert, MD  |  March 15, 2016

Friday, Nov. 13, 2015. The day Paris came under attack—again. What Came Before Not even 48 hours before that day, I had said my last goodbyes: the teary eyes, the final hugs, promising to stay in touch and, perhaps, see my friends next year at the ACR/ARHP Annual Meeting. Snap and share another photo. I…

2015 ACR/ARHP Annual Meeting: Unknowns Persist Around Sarcoidosis Etiology, Pathogenesis, Treatment

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—The Kveim-Siltzbach skin test for a diagnosis of sarcoidosis was developed in 1941, then popularized in 1961. Since then, the knowledge base about the disease has not expanded much, said Kristin Highland, MD, who has dual appointments at Cleveland Clinic’s Respiratory Institute and Orthopedics and Rheumatology Institute. “We don’t know a whole lot more…

2015 ACR/ARHP Annual Meeting: Genetic Links Emerge in Osteoarthritis

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—As researchers have delved into the genetics behind osteoarthritis (OA), genes that appear to be players in the disease have emerged, but there have also been curveballs thrown, with expectations not always matching up to the genetic realities, an expert said at the 2015 ACR/ARHP Annual Meeting. The genetic risk of acquiring OA is…

2015 ACR/ARHP Annual Meeting: Insights into the Microbiome

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—The organisms in the gut are remarkably malleable with diet, dangling the possibility that diseases could potentially be affected by the food that people eat, according to an expert here at the 2015 ACR/ARHP Annual Meeting. Diet Starting with studies of animal feces from zoos and from the wild, in which researchers found that…

2015 ACR/ARHP Annual Meeting: How to Identify, Manage Metabolic Myopathies & Their Mimics

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—An athletic 19-year-old male has an episode of rhabdomyolysis, a breakdown of muscle tissue that leads to contents of muscle fiber in the blood, after weight-lifting and basketball drills. But his labs come back normal. He cuts down on his exercise, but has a second episode four months later, then finally sees a rheumatologist…

2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—Rheumatologists have to look no further than the American College of Rheumatology guidelines to know that the options for patients with lupus nephritis are sometimes not very appealing. The first-line choices are either mycophenolate mofetil (MMF) plus glucocorticoids or cyclophosphamide (CYC), also with glucocorticoids—and all of their attendant side effects. The problem: evidence, said…

2015 ACR/ARHP Annual Meeting: Skin Issues in Rheumatic Diseases Present Challenges

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—A 40-year-old woman shows up in the clinic with scarring alopecia, with an area of hyperpigmentation on the rim of her scalp, extending from just behind the temple to behind her ears. An examination with a dermatoscope shows hyperkeratotic follicular plugging. The case—in this example, the discoid form of cutaneous lupus erythematosus (DLE)—is one…

  • « Previous Page
  • 1
  • …
  • 515
  • 516
  • 517
  • 518
  • 519
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences